Indivior PLC (INDV)
| Market Cap | 2.38B |
| Revenue (ttm) | 1.12B |
| Net Income (ttm) | 5.00M |
| Shares Out | 136.53M |
| EPS (ttm) | 0.02 |
| PE Ratio | 878.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 235,988 |
| Open | 18.23 |
| Previous Close | 17.93 |
| Day's Range | 17.50 - 18.36 |
| 52-Week Range | n/a |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 37.00 (+110.71%) |
| Earnings Date | Apr 25, 2024 |
About INDV
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUB... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for INDV stock is "Strong Buy" and the 12-month stock price forecast is $37.0.
News
Indivior Announces Q1 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
This head-to-head pharmacodynamic study in healthy volunteers examined the ability of both OPVEE and intranasal naloxone to reverse opioid-induced respiratory depression, which is the shallow and slow...
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation
RICHMOND, Va. , Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Cour...
Drugmaker Indivior consults on moving primary listing from London to US
UK-listed drugmaker Indivior Plc has begun consulting shareholders on shifting its primary listing to the United States by the middle of this year, it said on Thursday, after reporting a 27% jump in a...
Indivior Announces Q4 / FY 2023 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.
Indivior Announces Q3 2023 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023.
Indivior to pay $385 mln to end Suboxone monopoly lawsuits
Drugmaker Indivior said on Monday it will pay $385 million to settle a lawsuit brought by direct purchasers on claims it illegally suppressed generic competition for its opioid addiction treatment Sub...
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
- Alar's Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment for OUD - RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment co...
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada
Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy. Data published in the Journal of Addition Medicine RICHMOND, Va.
Click Therapeutics Announces Collaboration with Indivior to Develop and Commercialize Novel Prescription Digital Therapeutics in Substance Use Disorders
NEW YORK--(BUSINESS WIRE)--Click Therapeutics announces exclusive multi-product agreement with Indivior to develop and commercialize prescription digital therapeutics in SUD.
Indivior to pay $30 million to settle health plans' Suboxone claims
Indivior has agreed to pay $30 million to settle a class action lawsuit filed in a U.S. court by health plans accusing the drugmaker of illegally suppressing generic competition for its opioid addicti...
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
RICHMOND, Va. , Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agree...
Indivior Announces Q2/H1 2023 Financial Results
SLOUGH, United Kingdom, and RICHMOND, Va. , July 27, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending June 30, 2023.
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence
RICHMOND, Va. , June 14, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the acceptance of four abstracts for presentation at the 85th Annual Scientific Meeting of the College on ...
Indivior CEO Mark Crossley on company mission: We help people suffering from addiction
Indivior CEO Mark Crossley joins 'Squawk Box' to discuss the company's mission, demand for substance abuse treatment, the opioid epidemic, and more.
Indivior to Commence Trading on Nasdaq
Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment; Company Will Maintain Premium Listing on London Stock Exchange RICHMOND, Va. , June 12, 2023 /PRNewswire/ -- Indivior P...
Indivior reaches deal to resolve states' monopoly claim over opioid addiction drug
Indivior Plc said on Friday its unit had agreed to pay $102.5 million to settle a lawsuit by multiple state attorneys general accusing it of using illegal tactics to shield its opioid addiction treatm...
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims
RICHMOND, Va. , June 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement to ...
Indivior To Participate In Upcoming Investor Conferences
SLOUGH, England and RICHMOND, Va. , May 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events: Jefferies Healthcare Conference – N...
Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th
RICHMOND, Va. , May 23, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that its registration statement on Form 20-F required for the additional U.S. listing of its ordinary shares is no...
Indivior Announces Q1 2023 Financial Results
SLOUGH, U.K., and Richmond, Va., April 27, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023. The earnings release, investor pres...
Indivior To Participate In Bank of America Global Healthcare Conference 2023
SLOUGH, UK and RICHMOND, Va. , April 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event: Bank of America Global Healthcare Confe...
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
Combination Strengthens Indivior's Addiction Treatment and Science Portfolio RICHMOND, Va. , March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that i...
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.
Narcan Owner Opiant to Be Acquired by Indivior for $145 Million
The combination of addiction-drug makers could tap into billions of dollars in settlement and federal funds aimed at expanding access to treatment.